Novel thyroxine hapten luminescent marker and synthetic method thereof

Abstract

The invention discloses a novel thyroxine hapten luminescent marker and a synthetic method thereof, wherein the synthetic method of the novel thyroxine hapten luminescent marker comprises the steps: A) preparing a trifluoroacetamide compound 2 crude product; B) preparing a trifluoroacetamide compound 3; C) preparing a trifluoroacetamide compound 4; D) preparing a thyroxine methyl ester compound 5; E) preparing a thyroxine methyl ester compound 6; F) preparing a thyroxine methyl ester compound 7; and G) preparing the target product acridine marked novel thyroxine methyl ester. The invention provides the novel compound for chemiluminescence detection of thyroxine and the synthetic route and method thereof; the small-molecular marker is easy to purify, can achieve industrialized production, and improves the detection sensitivity. The defects that protein macromolecular compounds used in conventional detection reagents are expensive and allow differences to be easily produced in the production process are solved.

Description

technical field [0001] The invention belongs to the field of organic synthesis, and in particular relates to a synthesis method of a novel thyroxine hapten luminescent marker. Background technique [0002] Existing immunoassay methods include radioimmunoassay, electrochemiluminescence immunoassay, chemiluminescence immunoassay and enzyme-linked immunoassay. Chemiluminescence immunoassay has been widely used abroad in recent years because of its high sensitivity, good precision, wide detection linear range, stable markers, easy operation and no radioactive pollution. There are currently four types of markers commonly used in chemiluminescent immunoassays: luminol, isoluminol, acridinium ester derivatives, horseradish peroxidase, and alkaline phosphatase. Among them, the detection of thyroxine in the acridine body system is realized by the competition method, but at present, most of the international clinical diagnostic kits use AE·NHS labeled protein macromolecules, AE·NHS m...

AI Technical Summary

Problems solved by technology

Among them, the detection of thyroxine in the acridine body system is realized by the competition method, but at present, most of the international clinical diagnostic kits use AE·NHS labeled protein macromolecules, AE·NHS markers are easy to hydrolyze and have poor thermal stability. Short shelf life and expensive

[0003] Most of the existing kits for the determination of thyroxine use AE·NHS to label protein macromolecules. Such markers are easy to hydrolyze, have poor thermal stability, and are relatively susceptible to external interference. The difference between production batches is large, which directly increases the unit testing cost.

Images